There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > REGULATORY
REGULATORY
- MHLW Reports Package Insert Revisions for Elplat
September 28, 2012
- Price Gap between Long-Listed Products, Generics Should Be Retained: Mr Chikazawa of MHLW
September 28, 2012
- MHLW Asks FPMAJ to Revise Precaution Section of Package Inserts for 13 APIs Including Diclofenac
September 28, 2012
- HSB to Make “Steady Efforts” Against Lifestyle Diseases: Director General Yajima
September 28, 2012
- Latest Proposal to Discuss Reference Pricing System Gets Cold Shoulder from CSIMC
September 26, 2012
- MHLW Reports 1 Dispensing Error Due to Name Similarity; Almarl Already Renamed
September 24, 2012
- MHLW Issues Notification to Prohibit Dispensing Point Services
September 21, 2012
- MHLW to Introduce Brand Name Rules for Combination Injectables to Prevent Medical Accidents
September 21, 2012
- Reimbursement of Generic Drugs Used Off-Label “Not Necessarily Illegal,” Government Says
September 20, 2012
- Half of Hospitals Participating in Network Play Central Role: MHLW FY2011 Survey
September 19, 2012
- MHLW Eyes Introduction of Piecework Payment for Clinical Trials at 54 Hospitals by FY2016
September 18, 2012
- MHLW Budget Request Includes Funds for Database of Information on Patients with Cancer, Lifestyle Diseases
September 18, 2012
- MHLW Calls for Self-Inspections at Japanese Pharmaceutical Firms after “Gutter Oil”-Made Antibiotic Intermediates Found in China
September 14, 2012
- MHLW Instructs Daiichi Sankyo to Issue Blue Letter on Ranmark Following Two Reported Deaths
September 13, 2012
- MEXT Calls for 21 Billion Yen for Special Priority Area of Healthcare Innovation in FY2013 Budget Request
September 12, 2012
- Osaka District Court to Issue Ruling on Actos Patent Suit on Sept. 27
September 12, 2012
- MHLW Issues Q&As on Drug Risk Management Plans to Prefectures
September 12, 2012
- MHLW Notifies of Expected Additional Indications for 3 APIs
September 12, 2012
- PAFSC’s 2nd Committee Designates 7 products as Orphan Drugs Including Glioblastoma Treatment Bevacizumab
September 11, 2012
- Chairman Breaks Tie, Votes to Continue Lower House Discussions on Bill to Establish 3rd-Party Organization
September 11, 2012
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…